Last reviewed · How we verify
Hidradenitis suppurativa
Approved treatments
- Abrilada · AbbVie
Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - Humira · AbbVie
Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - CYLTEZO · BOEHRINGER INGELHEIM
- Humira · Sohag University
Clinical guidelines
- FDA label — 1L|2L
Treatment of moderate to severe hidradenitis suppurativa in adult patients. - FDA label — 1L|2L
Treatment of moderate to severe hidradenitis suppurativa in adult patients.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Hidradenitis suppurativa patent landscape — cliff calendar, originator estates, attackable patents
- Hidradenitis suppurativa treatment landscape brief
- Hidradenitis suppurativa treatment updates RSS
Frequently asked questions about Hidradenitis suppurativa
What drugs treat Hidradenitis suppurativa?
Tracked treatments include Abrilada, Humira, CYLTEZO.
What is the treatment for Hidradenitis suppurativa?
Standard treatment for Hidradenitis suppurativa includes Abrilada, Humira, CYLTEZO. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Hidradenitis suppurativa?
FDA label publishes guidelines for Hidradenitis suppurativa. 2 guideline references tracked.
Related
- Treatment landscape: Hidradenitis suppurativa patent cliff · Hidradenitis suppurativa CI report
- Treatment: Abrilada · AbbVie
- Treatment: Humira · AbbVie
- Treatment: CYLTEZO · BOEHRINGER INGELHEIM
- Treatment: Humira · Sohag University
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing